Fallout from the recent controversy over diabetes drug Avandia is having an impact on its manufacturer’s profits. GlaxoSmithKline, one of the foremost drug companies in the world, have posted second-quarter earnings that fall below expectations. Glaxo are planning to expand their stock buyback program, which may help to alleviate investor concerns.
Glaxo says that despite the hit to their profit, they will buy back $25 billion of stock in the next few years. The news put Glaxo shares back up. Glaxo’s first quarter earnings were approximately $2.69 billion.
Avandia has been through a media rollercoaster in recent months, following a controversial report published in the New England Journal of Medicine . Avandia has slumped in sales following press scrutiny.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…